# Thera-T Pharmaceutics

**Type:** venture
**Status:** Draft
**Confidence:** Medium
**Focus:** immuno-oncology, blood cancer, T-cell therapy, multi-antigen targeting, university spinout
**Stage:** Preclinical (U2TAH-incubated; approximately $400K funding; animal studies ongoing)
**Location:** Salt Lake City, UT
**Updated:** 2026-06-19
**Needs-reviewed:** 2026-06-19
**Hero:** https://picsum.photos/seed/thera-t-pharmaceutics-2026/1600/1100
**Relates:** cites [Official Website: Thera-T Pharmaceutics](thera-t-pharmaceutics-official-website.md)

## Summary

Thera-T Pharmaceutics is an early-stage University of Utah College of Pharmacy spinout, incubated at U2TAH (Huntsman Cancer Institute therapeutics accelerator), developing MATCH — Multi-Antigen T-Cell Hybridizers — a self-assembling two-component construct designed to direct T cells to multiple cancer antigens simultaneously. The company targets B-cell leukemias, lymphomas, and multiple myeloma. Founder Tommy Gambles is a postdoctoral researcher building on Dr. Jindřich Kopeček's polymer immunotherapy laboratory. The company received the University of Utah's 2025 Breakthrough Technology of the Year award. Animal studies are ongoing; approximately $400K in funding has been raised.

## Impact

Blood cancer immunotherapy has produced genuine clinical successes — CAR-T therapies like Kymriah and Yescarta, and bispecific antibodies like blinatumomab — but a major failure mode is antigen escape: cancer cells that downregulate the single surface marker a therapy targets and thereby evade killing. MATCH's multi-antigen design addresses this directly. By engaging multiple antigens simultaneously, the construct makes it harder for tumor cells to escape through single-antigen loss.

The self-assembling two-component design carries a second potential advantage: current CAR-T manufacturing requires viral vector engineering of patient T cells, a process that is expensive, slow, and difficult to standardize. MATCH's non-viral, self-assembling approach could substantially reduce manufacturing complexity and cost if it performs in clinical settings as the design intends.

The U of U's 2025 Breakthrough Technology of the Year award signals institutional recognition of the approach, though preclinical validation is the relevant evidentiary bar.

## What They Are Building

MATCH — Multi-Antigen T-Cell Hybridizers — consists of two self-assembling components that together redirect T cells to recognize multiple cancer surface antigens on the same tumor cell. The constructs are designed to work without viral manufacturing, which distinguishes them from current gene-edited CAR-T approaches.

The company is also developing an AI-guided dosing model that personalizes treatment parameters based on tumor burden, antigen expression levels, and T-cell counts in individual patients. This computational layer adds complexity but, if validated, could enable more precise dosing than current fixed-regimen immunotherapy.

Current targets are B-cell malignancies: B-cell leukemia, non-Hodgkin lymphoma, and multiple myeloma — all cancers with defined surface-marker profiles that make multi-antigen targeting feasible.

## What They Need Now

At approximately $400K in funding, Thera-T is operating at lab and early animal-study scale. Likely needs include additional non-dilutive federal funding (SBIR/STTR, NIH NCI grants), early angel or seed investment from oncology-focused life sciences investors, preclinical contract research organization (CRO) partnerships for animal studies, and eventual regulatory guidance for IND filing. The company also appears to need manufacturing development support for the self-assembling construct chemistry.

## Who Could Help

The Huntsman Cancer Institute is the most proximate institutional partner, given the U2TAH incubation relationship and access to clinical oncology expertise. Blood cancer clinicians and researchers at HCI or other academic medical centers could accelerate translational validation. Oncology-focused seed and early-stage investors with patience for preclinical timelines (three to five years to IND is a reasonable baseline estimate) are the relevant capital class. CRO partners with lymphoma and leukemia xenograft experience, and IP counsel familiar with polymer and immunotherapy patent landscapes, would also be valuable.

## Utah Context

The Huntsman Cancer Institute at the University of Utah is a National Cancer Institute-designated comprehensive cancer center with meaningful expertise in hematologic malignancies. U2TAH, HCI's therapeutics accelerator, has provided the incubation infrastructure for Thera-T. This is a genuine strength — having direct access to HCI's clinical expertise and patient populations accelerates the path from bench to IND more than most early-stage spinouts achieve.

The blood cancer immunotherapy space is crowded nationally, but Thera-T's multi-antigen and non-viral manufacturing differentiators could carve a meaningful niche if animal data and eventual human data support the mechanism.

## Evidence

- [Official Website: Thera-T Pharmaceutics](thera-t-pharmaceutics-official-website.md)

## See Also

## Open Questions

- What do the current animal studies show — which cancer models, what response rates, what toxicity profile?
- Has an IND application timeline been established?
- How does the AI-guided dosing model work technically, and what data is required to validate and personalize it?
- MATCH's self-assembling design is novel — has the two-component assembly been demonstrated robustly in primary human T cells?
- $400K is sufficient for early animal studies but not for IND-enabling studies, let alone clinical trials; what is the fundraising plan?
- Blood cancer immunotherapy is a crowded space with multiple approved CAR-T and bispecific products — what clinical differentiation does MATCH offer in head-to-head preclinical comparisons?
- The placeholder hero should be replaced with a cleared laboratory or science photograph when rights are confirmed.